Clinical Trials Browser

Phase 3 × Carcinosarcoma × Congresses as Topic × Clear all

NCT04214067 2026-05-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Phase 3 Active not recruiting

Carcinosarcoma